Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Consultancy and ABPI Benefit From Former NICE Grandee Longson’s HTA Knowhow

Executive Summary

Pharma companies will be able to benefit from Carole Longson’s considerable expertise on two fronts. After 18 years in top-level roles at UK HTA body NICE, Longson is joining international consultancy group NDA as well as the UK industry association, the ABPI.

You may also be interested in...



Veteran NICE Director Longson Leaves UK HTA Body For New Role At ABPI

The UK R&D-based industry body will benefit from Carole Longson’s huge expertise in health technology assessment-related matters. Longson is leaving NICE after 17 years to take up the new role of chief scientific officer at the Association of the British Pharmaceutical Industry.

Sanofi Seeks Double Vaccine Approval Nod In EU

The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.

EU Fast-Track Review In Store For Takeda’s Dengue Vaccine

Takeda will soon seek EU approval of its dengue vaccine candidate. The marketing application will be fast-tracked, as will the applications for Regeneron's evinacumab and bluebird bio's eli-cel Lenti-D gene therapy.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel